Cinctive Capital Management’s Haemonetics HAE Stock Holding History

Cinctive Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-139,388	Closed	-$12.5M	–	424
2023 Q3	$12.5M	Buy	139,388 +81,086	+139%	+$7.24M	0.62%	41
2023 Q2	$4.96M	Sell	58,302 -116,823	-67%	-$9.88M	0.17%	195
2023 Q1	$14.5M	Buy	175,125 +104,635	+148%	+$8.47M	0.48%	55
2022 Q4	$5.54M	Sell	70,490 -90,036	-56%	-$7.24M	0.27%	113
2022 Q3	$11.9M	Buy	+160,526	New	+$11.5M	0.5%	50
2021 Q4	–	Sell	-54,351	Closed	-$3.84M	–	585
2021 Q3	$3.84M	Buy	54,351 +38,592	+245%	+$2.44M	0.19%	191
2021 Q2	$1.05M	Buy	+15,759	New	+$1.12M	0.05%	357
2021 Q1	–	Sell	-37,733	Closed	-$4.48M	–	444
2020 Q4	$4.48M	Buy	37,733 +16,649	+79%	+$1.79M	0.37%	111
2020 Q3	$1.84M	Buy	+21,084	New	+$1.84M	0.16%	220

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cinctive Capital Management's HAE Position: Q4 2023 in Review

Cinctive Capital Management sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 139,388 shares — an estimated $12.5M sold.

Cinctive Capital Management first reported a position in HAE in Q3 2020 and held it in 9 quarters. The position peaked at $14.5M in Q1 2023. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

Cinctive Capital Management reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
Cinctive Capital Management sold 139,388 Haemonetics shares in Q4 2023, an estimated $12.5M.
Cinctive Capital Management first reported a position in Haemonetics in Q3 2020 and held it in 9 quarters.
Cinctive Capital Management's Haemonetics position peaked at $14.5M in Q1 2023.
295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on Cinctive Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.